Big Movers: IGI Laboratories, Inc. (NYSEMKT:IG), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), OM Group Inc. (NYSE:OMG), Tesla Motors Inc (NASDAQ:TSLA)

IGI Laboratories, Inc. (NYSEMKT:IG) belongs to Healthcare sector. Its net profit margin is 31.10% and weekly performance is 12.07%. On last trading day company shares ended up $7.15. IGI Laboratories, Inc. (NYSEMKT:IG) distance from 50-day simple moving average (SMA50) is 17.86%. IGI Laboratories, Inc. (NYSEMKT:IG) on 9 July, announced it has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The Company now markets seven products in twelve presentations in an IGI label.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares advanced 14.51% in last trading session and ended the day at $62.03. ATRA return on assets is -31.00%. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) quarterly performance is 29.55%. ATARA Biotherapeutics Inc. (NASDAQ:ATRA) announced the pricing of its underwritten public offering of 3,461,538 shares of its common stock at a public offering price of $52.00 per share. In addition, Atara Bio granted the underwriters a 30-day option to purchase up to an additional 519,230 shares of common stock at the public offering price. All of the shares in the offering will be sold by Atara Bio. The offering is expected to close on July 15, 2015, subject to customary closing conditions.

On 13 July, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares advanced 5.10% and was closed at $1.65. AVEO EPS growth in last 5 year was 48.30%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) year to date (YTD) performance is 96.43%. On 2 July, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) declared that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors.

OM Group Inc. (NYSE:OMG) ended the last trading day at $34.54. Company weekly volatility is calculated as 1.25% and price to cash ratio as 20.00. OM Group Inc. (NYSE:OMG) showed a weekly performance of -0.72%. On 6 July, OM Group Inc. (NYSE:OMG) has announced the expiration of the 35-day “go shop” period pursuant to the terms of the previously announced merger agreement dated May 31, 2015 among the company and funds managed by affiliates of Apollo Global Management, LLC and a wholly-owned subsidiary of Platform Specialty Product.

Tesla Motors Inc (NASDAQ:TSLA) ended the last trading day at $262.16. Company weekly volatility is calculated as 3.01% and price to cash ratio as 21.94. Tesla Motors Inc (NASDAQ:TSLA) showed a weekly performance of -6.28%. Tesla Motors Inc (NASDAQ:TSLA) has hired Ganesh Srivats as its vice president for sales in North America. Srivats is the former senior vice president at British luxury fashion brand Burberry.

Leave a Reply

Your email address will not be published. Required fields are marked *